Investigators enrolled adults with obesity or overweight plus at least one weight-related comorbidity into a two-arm, parallel-group randomized trial. All participants received weekly tirzepatide and were then randomized to either thrice-weekly supervised resistance exercise (REx) training or to continue usual activities for 40 weeks. The trial team reported that most participants tolerated up-titration of tirzepatide to 15 mg weekly. Adherence to the REx program was high — the trial data indicated 91% attendance — and the intervention was delivered alongside the pharmacologic regimen without modification of the allocated drug. The Australian New Zealand Clinical Trials Registry identifier is ACTRN12623001236684.
The excerpted report did not include full participant baseline characteristics, detailed randomization procedures, or complete adverse-event tables. The published abstract and main text provided outcome summaries but did not reproduce the full statistical analysis plan or per-protocol versus intention-to-treat breakdowns in the material supplied here.
The trial used dual-energy X-ray absorptiometry (DXA) to assess co-primary endpoints: change in total fat mass and change in total lean soft tissue mass. Weight loss was large and essentially equivalent between groups: the tirzepatide-only group lost −22.61 kg and the tirzepatide-plus-resistance group lost −22.28 kg (P = 0.694). Change in total fat mass did not differ meaningfully between arms (T = −17.19 kg, T+REx = −17.98 kg; P = 0.700), with a reported between-group difference of −0.77 kg (95% CI −2.14 to 0.60 kg).
In contrast, the addition of resistance training altered the trajectory of lean-tissue loss. Total lean soft tissue mass fell with tirzepatide alone (T = −4.67 kg) but to a lesser extent when combined with resistance exercise (T+REx = −3.57 kg). The authors reported a statistically significant between-group difference of 1.09 kg in preserved lean soft tissue mass (95% CI 0.43–1.75 kg; P < 0.001). These data indicate that, despite equivalent total weight and fat loss, supervised resistance training attenuated the decline in whole-body lean soft tissue measured by DXA.
Appendicular compartments followed the same pattern. Loss of appendicular lean soft tissue mass was reduced in the combined therapy arm (T = −3.55 kg; T+REx = −2.92 kg; P < 0.001), suggesting that limb muscle compartments benefited from the resistance program during pharmacologically induced weight loss.
Muscle function did not mirror weight change. The study team observed decreases in upper- and lower-body strength with tirzepatide monotherapy: bench press strength fell by 4.09 kg, lat pulldown by 4.42 kg and knee extension by 4.42 kg. By contrast, participants randomized to tirzepatide plus resistance exercise experienced increases in these measures: bench press +4.68 kg, lat pulldown +8.58 kg and knee extension +5.88 kg. All comparisons of the T+REx group versus tirzepatide alone reached P < 0.001 according to the reported results. These divergent strength trajectories, occurring alongside similar overall weight loss, indicate functional benefit from the added exercise prescription.
The published excerpt did not provide detailed information on the testing protocols used for each strength measure (for example, whether one-repetition maximum testing or isokinetic dynamometry was used) nor did it give timecourse plots of strength change across the 40-week intervention in the material supplied here.
Tirzepatide was described as safe in the cohort and was generally tolerated during dose escalation to 15 mg weekly for most participants. The resistance training program achieved a reported 91% adherence, which the investigators presented as evidence that supervised muscle-strengthening programs can be implemented feasibly in adults receiving incretin-based pharmacotherapy. The report did not include detailed adverse-event rates by treatment arm in the excerpt provided, so the precise nature and frequency of any drug- or exercise-related adverse effects cannot be reproduced from this text alone.
The authors placed these results within a broader evidence base showing large reductions in body weight and fat mass with incretin mimetics, and prior reports of 11–14% losses in total body lean soft tissue mass measured by DXA with these agents. They noted that skeletal muscle volume measured by MRI can also fall with incretin mimetics, albeit sometimes accompanied by reduced muscle fat infiltration. Given the rapid uptake of potent incretin therapies for obesity, the trial addressed a clinical question of immediate relevance: can a widely available, non-pharmacological intervention mitigate lean mass and strength loss when potent weight-loss drugs are started?
This trial’s findings answer that question in the affirmative for supervised resistance training: the combination preserved more lean soft tissue and improved muscle strength compared with tirzepatide alone, despite similar total weight and fat loss.
The provided manuscript excerpt did not present full methodological detail, including complete baseline participant characteristics, the precise resistance training protocol (specific exercises, loads, progression metrics beyond frequency), comprehensive adverse-event tables, or subgroup analyses by age or baseline muscle mass. The text also did not include the trial’s full statistical methods or sensitivity analyses in the material supplied here. Cardiovascular risk factor results were noted as secondary outcomes but were not reported numerically in the excerpt.
Unanswered clinical questions that remain, based on the presented material, include longer-term durability of lean mass and strength preservation after treatment cessation, the optimal resistance-training prescription for different age groups or frailty levels, and whether similar effects would be observed with other incretin mimetics or dosing regimens. Future reports or full trial supplements will need to supply the missing protocol details, adverse-event data and subgroup analyses to allow deeper clinical interpretation and to inform guideline recommendations.